MARK ANDREW SHERMAN Insider Trading $DLB Dolby Laboratories, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for MARK ANDREW SHERMAN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of MARK ANDREW SHERMAN. MARK ANDREW SHERMAN is EVP, GEN. COUN. & SECRTY in Dolby Laboratories, Inc. ($DLB).
MARK ANDREW SHERMAN in Dolby Laboratories, Inc.
Industry: PATENT OWNERS & LESSORS [6794]
Position of MARK ANDREW SHERMAN: EVP, GEN. COUN. & SECRTY
Holdings: 63,010 shares
Current Value: $2,999,906
Latest Transaction: Mar 03 2021
$DLB Market Capitalization: $4.88B
$DLB Previous Close: $47.61
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of MARK ANDREW SHERMAN in Dolby Laboratories, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 03 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 13,000 | 591,500 | 23,118 | |
| Mar 03 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 100.00 | 13,000 | 1,300,000 | 50,010 | 63 K to 50 K (-20.63 %) |
| Mar 03 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 13,000 | 591,500 | 63,010 | 50 K to 63 K (+25.99 %) |
| Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 13,000 | 591,500 | 36,118 | |
| Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 95.00 | 13,000 | 1,235,000 | 50,010 | 63 K to 50 K (-20.63 %) |
| Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 13,000 | 591,500 | 63,010 | 50 K to 63 K (+25.99 %) |
| Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 13,000 | 591,500 | 36,118 | |
| Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 95.00 | 13,000 | 1,235,000 | 50,010 | 63 K to 50 K (-20.63 %) |
| Feb 17 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 13,000 | 591,500 | 63,010 | 50 K to 63 K (+25.99 %) |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 23,118 | 1,051,869 | 0 | |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 2,882 | 131,131 | 49,118 | |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 92.23 | 496 | 45,746 | 50,010 | 50.5 K to 50 K (-0.98 %) |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.58 | 22,622 | 2,071,718 | 50,506 | 73.1 K to 50.5 K (-30.93 %) |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 23,118 | 1,051,869 | 73,128 | 50 K to 73.1 K (+46.23 %) |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 92.23 | 175 | 16,140 | 50,010 | 50.2 K to 50 K (-0.35 %) |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.48 | 2,707 | 247,635 | 50,185 | 52.9 K to 50.2 K (-5.12 %) |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 2,882 | 131,131 | 52,892 | 50 K to 52.9 K (+5.76 %) |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 92.23 | 227 | 20,936 | 50,010 | 50.2 K to 50 K (-0.45 %) |
| Feb 08 2021 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.68 | 1,436 | 131,649 | 50,237 | 51.7 K to 50.2 K (-2.78 %) |
| Dec 21 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.96 | 1,638 | 150,629 | 51,673 | 53.3 K to 51.7 K (-3.07 %) |
| Dec 21 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 91.03 | 1,612 | 146,740 | 53,311 | 54.9 K to 53.3 K (-2.94 %) |
| Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 92.08 | 30,553 | 2,813,320 | 30,553 | |
| Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 0.00 | 7,136 | 0 | 7,136 | |
| Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 91.66 | 337 | 30,888 | 54,923 | 55.3 K to 54.9 K (-0.61 %) |
| Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 90.62 | 3,065 | 277,748 | 55,260 | 58.3 K to 55.3 K (-5.26 %) |
| Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 92.08 | 1,637 | 150,735 | 58,325 | 60 K to 58.3 K (-2.73 %) |
| Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Grant | A | 0.00 | 14,272 | 0 | 59,962 | 45.7 K to 60 K (+31.24 %) |
| Dec 17 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 90.86 | 3,348 | 304,199 | 45,690 | 49 K to 45.7 K (-6.83 %) |
| Nov 05 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 45.50 | 1,582 | 71,981 | 23,118 | |
| Nov 05 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 42.98 | 23,418 | 1,006,506 | 0 | |
| Nov 05 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 80.00 | 1,582 | 126,563 | 49,038 | 50.6 K to 49 K (-3.13 %) |
| Nov 05 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 45.50 | 1,582 | 71,981 | 50,620 | 49 K to 50.6 K (+3.23 %) |
| Nov 05 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 80.00 | 23,418 | 1,873,459 | 49,038 | 72.5 K to 49 K (-32.32 %) |
| Nov 05 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 42.98 | 23,418 | 1,006,506 | 72,456 | 49 K to 72.5 K (+47.75 %) |
| Feb 20 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 42.98 | 20,000 | 859,600 | 48,418 | |
| Feb 20 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 73.00 | 20,000 | 1,460,000 | 48,651 | 68.7 K to 48.7 K (-29.13 %) |
| Feb 20 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 42.98 | 20,000 | 859,600 | 68,651 | 48.7 K to 68.7 K (+41.11 %) |
| Feb 10 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 37.35 | 29,821 | 1,113,814 | 0 | |
| Feb 10 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 42.98 | 6,794 | 292,006 | 68,418 | |
| Feb 10 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 71.99 | 29,821 | 2,146,942 | 48,651 | 78.5 K to 48.7 K (-38.00 %) |
| Feb 10 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 37.35 | 29,821 | 1,113,814 | 78,472 | 48.7 K to 78.5 K (+61.30 %) |
| Feb 10 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 72.02 | 6,794 | 489,294 | 48,651 | 55.4 K to 48.7 K (-12.25 %) |
| Feb 10 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 42.98 | 6,794 | 292,006 | 55,445 | 48.7 K to 55.4 K (+13.96 %) |
| Feb 06 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 37.35 | 38,176 | 1,425,874 | 29,821 | |
| Feb 06 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 33.15 | 5,209 | 172,678 | 0 | |
| Feb 06 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 71.94 | 38,176 | 2,746,309 | 48,651 | 86.8 K to 48.7 K (-43.97 %) |
| Feb 06 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 37.35 | 38,176 | 1,425,874 | 86,827 | 48.7 K to 86.8 K (+78.47 %) |
| Feb 06 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 72.00 | 5,209 | 375,062 | 48,651 | 53.9 K to 48.7 K (-9.67 %) |
| Feb 06 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 33.15 | 5,209 | 172,678 | 53,860 | 48.7 K to 53.9 K (+10.71 %) |
| Feb 06 2020 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 72.03 | 6,615 | 476,452 | 48,651 | 55.3 K to 48.7 K (-11.97 %) |
| Dec 18 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 68.40 | 60,000 | 4,104,000 | 60,000 | |
| Dec 18 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 0.00 | 6,600 | 0 | 6,600 | |
| Dec 18 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 68.40 | 1,612 | 110,261 | 55,266 | 56.9 K to 55.3 K (-2.83 %) |
| Dec 18 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Grant | A | 0.00 | 13,200 | 0 | 56,878 | 43.7 K to 56.9 K (+30.22 %) |
| Dec 18 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 67.75 | 4,898 | 331,840 | 43,678 | 48.6 K to 43.7 K (-10.08 %) |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 37.35 | 6,040 | 225,594 | 67,997 | |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 33.15 | 1,460 | 48,399 | 0 | |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 33.15 | 29,790 | 987,539 | 1,460 | |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 33.15 | 20,210 | 669,962 | 5,209 | |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 67.73 | 6,040 | 409,089 | 48,576 | 54.6 K to 48.6 K (-11.06 %) |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 37.35 | 6,040 | 225,594 | 54,616 | 48.6 K to 54.6 K (+12.43 %) |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 67.73 | 1,460 | 98,886 | 48,576 | 50 K to 48.6 K (-2.92 %) |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 33.15 | 1,460 | 48,399 | 50,036 | 48.6 K to 50 K (+3.01 %) |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 67.50 | 29,790 | 2,010,825 | 48,576 | 78.4 K to 48.6 K (-38.01 %) |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 33.15 | 29,790 | 987,539 | 78,366 | 48.6 K to 78.4 K (+61.33 %) |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 67.50 | 20,210 | 1,364,175 | 48,576 | 68.8 K to 48.6 K (-29.38 %) |
| Aug 02 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 33.15 | 20,210 | 669,962 | 68,786 | 48.6 K to 68.8 K (+41.60 %) |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 33.15 | 5,063 | 167,838 | 25,419 | |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 33.15 | 19,518 | 647,022 | 30,482 | |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 30.49 | 2,919 | 89,000 | 0 | |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 65.00 | 5,063 | 329,095 | 48,179 | 53.2 K to 48.2 K (-9.51 %) |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 33.15 | 5,063 | 167,838 | 53,242 | 48.2 K to 53.2 K (+10.51 %) |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 65.09 | 19,518 | 1,270,452 | 48,179 | 67.7 K to 48.2 K (-28.83 %) |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 33.15 | 19,518 | 647,022 | 67,697 | 48.2 K to 67.7 K (+40.51 %) |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 65.01 | 2,919 | 189,758 | 48,179 | 51.1 K to 48.2 K (-5.71 %) |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 30.49 | 2,919 | 89,000 | 51,098 | 48.2 K to 51.1 K (+6.06 %) |
| Feb 25 2019 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 64.99 | 1,764 | 114,640 | 48,179 | 49.9 K to 48.2 K (-3.53 %) |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 64.60 | 52,000 | 3,359,200 | 52,000 | |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 64.60 | 52,000 | 3,359,200 | 52,000 | |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 64.60 | 26,000 | 1,679,600 | 26,000 | |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 64.60 | 26,000 | 1,679,600 | 26,000 | |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 65.15 | 400 | 26,062 | 49,943 | 50.3 K to 49.9 K (-0.79 %) |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 65.15 | 400 | 26,062 | 49,943 | 50.3 K to 49.9 K (-0.79 %) |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 64.49 | 4,326 | 279,001 | 50,343 | 54.7 K to 50.3 K (-7.91 %) |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 64.49 | 4,326 | 279,001 | 50,343 | 54.7 K to 50.3 K (-7.91 %) |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Grant | A | 0.00 | 13,000 | 0 | 54,669 | 41.7 K to 54.7 K (+31.20 %) |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Grant | A | 0.00 | 13,000 | 0 | 54,669 | 41.7 K to 54.7 K (+31.20 %) |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 66.17 | 6,387 | 422,628 | 41,669 | 48.1 K to 41.7 K (-13.29 %) |
| Dec 19 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 66.17 | 6,387 | 422,628 | 41,669 | 48.1 K to 41.7 K (-13.29 %) |
| Aug 27 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 30.49 | 10,000 | 304,900 | 2,919 | |
| Aug 27 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 70.00 | 10,000 | 700,000 | 48,056 | 58.1 K to 48.1 K (-17.22 %) |
| Aug 27 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 30.49 | 10,000 | 304,900 | 58,056 | 48.1 K to 58.1 K (+20.81 %) |
| Feb 27 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 30.49 | 10,000 | 304,900 | 12,919 | |
| Feb 27 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 65.00 | 10,000 | 650,000 | 47,566 | 57.6 K to 47.6 K (-17.37 %) |
| Feb 27 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 30.49 | 10,000 | 304,900 | 57,566 | 47.6 K to 57.6 K (+21.02 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 30.49 | 31,554 | 962,081 | 22,919 | |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 30.49 | 7,227 | 220,351 | 54,473 | |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 28.24 | 41,219 | 1,164,025 | 0 | |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 63.05 | 500 | 31,525 | 47,566 | 48.1 K to 47.6 K (-1.04 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 62.17 | 3,254 | 202,306 | 48,066 | 51.3 K to 48.1 K (-6.34 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 61.56 | 18,000 | 1,107,994 | 51,320 | 69.3 K to 51.3 K (-25.97 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 60.44 | 9,800 | 592,274 | 69,320 | 79.1 K to 69.3 K (-12.39 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 30.49 | 31,554 | 962,081 | 79,120 | 47.6 K to 79.1 K (+66.34 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 63.20 | 7,227 | 456,746 | 47,566 | 54.8 K to 47.6 K (-13.19 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 30.49 | 7,227 | 220,351 | 54,793 | 47.6 K to 54.8 K (+15.19 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 63.67 | 7,401 | 471,239 | 47,566 | 55 K to 47.6 K (-13.46 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 63.24 | 33,818 | 2,138,583 | 54,967 | 88.8 K to 55 K (-38.09 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 28.24 | 41,219 | 1,164,025 | 88,785 | 47.6 K to 88.8 K (+86.66 %) |
| Feb 09 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 63.10 | 1,554 | 98,057 | 47,566 | 49.1 K to 47.6 K (-3.16 %) |
| Jan 16 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 28.24 | 10,000 | 282,400 | 41,219 | |
| Jan 16 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 65.00 | 10,000 | 650,000 | 49,120 | 59.1 K to 49.1 K (-16.91 %) |
| Jan 16 2018 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 28.24 | 10,000 | 282,400 | 59,120 | 49.1 K to 59.1 K (+20.36 %) |
| Dec 19 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 62.32 | 56,000 | 3,489,920 | 56,000 | |
| Dec 19 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 62.32 | 28,000 | 1,744,960 | 28,000 | |
| Dec 19 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 62.22 | 1,665 | 103,591 | 49,120 | 50.8 K to 49.1 K (-3.28 %) |
| Dec 19 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 62.58 | 2,929 | 183,296 | 50,785 | 53.7 K to 50.8 K (-5.45 %) |
| Dec 19 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 62.32 | 1,817 | 113,235 | 53,714 | 55.5 K to 53.7 K (-3.27 %) |
| Dec 19 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Grant | A | 0.00 | 14,000 | 0 | 55,531 | 41.5 K to 55.5 K (+33.71 %) |
| Dec 19 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 60.99 | 4,894 | 298,485 | 41,531 | 46.4 K to 41.5 K (-10.54 %) |
| Oct 20 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 28.24 | 7,000 | 197,680 | 51,219 | |
| Oct 20 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 60.00 | 7,000 | 420,002 | 45,935 | 52.9 K to 45.9 K (-13.22 %) |
| Oct 20 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 28.24 | 7,000 | 197,680 | 52,935 | 45.9 K to 52.9 K (+15.24 %) |
| Sep 15 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 28.24 | 14,000 | 395,360 | 58,219 | |
| Sep 15 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 57.50 | 7,000 | 402,500 | 45,935 | 52.9 K to 45.9 K (-13.22 %) |
| Sep 15 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 55.00 | 7,000 | 385,000 | 52,935 | 59.9 K to 52.9 K (-11.68 %) |
| Sep 15 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 28.24 | 14,000 | 395,360 | 59,935 | 45.9 K to 59.9 K (+30.48 %) |
| Mar 31 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 28.24 | 6,000 | 169,440 | 72,219 | |
| Mar 31 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 52.50 | 6,000 | 315,000 | 45,935 | 51.9 K to 45.9 K (-11.55 %) |
| Mar 31 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 28.24 | 6,000 | 169,440 | 51,935 | 45.9 K to 51.9 K (+13.06 %) |
| Mar 02 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 28.24 | 6,000 | 169,440 | 78,219 | |
| Mar 02 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 50.00 | 6,000 | 300,000 | 45,935 | 51.9 K to 45.9 K (-11.55 %) |
| Mar 02 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 28.24 | 6,000 | 169,440 | 51,935 | 45.9 K to 51.9 K (+13.06 %) |
| Feb 01 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | M | 28.24 | 10,000 | 282,400 | 84,219 | |
| Feb 01 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 47.59 | 10,000 | 475,859 | 45,935 | 55.9 K to 45.9 K (-17.88 %) |
| Feb 01 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Buy | M | 28.24 | 10,000 | 282,400 | 55,935 | 45.9 K to 55.9 K (+21.77 %) |
| Feb 01 2017 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 47.67 | 2,409 | 114,840 | 45,935 | 48.3 K to 45.9 K (-4.98 %) |
| Dec 22 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 46.07 | 1,119 | 51,548 | 48,344 | 49.5 K to 48.3 K (-2.26 %) |
| Dec 22 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 46.30 | 1,879 | 86,998 | 49,463 | 51.3 K to 49.5 K (-3.66 %) |
| Dec 19 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 45.50 | 52,000 | 2,366,000 | 52,000 | |
| Dec 19 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Option Exercise | A | 45.50 | 26,000 | 1,183,000 | 26,000 | |
| Dec 19 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 45.96 | 1,082 | 49,727 | 51,342 | 52.4 K to 51.3 K (-2.06 %) |
| Dec 19 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 45.71 | 2,271 | 103,799 | 52,424 | 54.7 K to 52.4 K (-4.15 %) |
| Dec 19 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 45.86 | 1,817 | 83,328 | 54,695 | 56.5 K to 54.7 K (-3.22 %) |
| Dec 19 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 45.50 | 2,632 | 119,756 | 56,512 | 59.1 K to 56.5 K (-4.45 %) |
| Dec 19 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Grant | A | 0.00 | 13,000 | 0 | 59,144 | 46.1 K to 59.1 K (+28.17 %) |
| Dec 01 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Gift | G | 0.00 | 97 | 0 | 46,144 | 46.2 K to 46.1 K (-0.21 %) |
| Dec 01 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Gift | G | 0.00 | 98 | 0 | 46,241 | 46.3 K to 46.2 K (-0.21 %) |
| Aug 11 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Sell | S | 49.52 | 6,152 | 304,629 | 46,339 | 52.5 K to 46.3 K (-11.72 %) |
| Aug 11 2016 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 49.73 | 3,705 | 184,250 | 52,491 | 56.2 K to 52.5 K (-6.59 %) |
| Dec 22 2015 | DLB | Dolby Laboratories ... | SHERMAN MARK ANDREW | EVP, GEN. COUN. & S ... | Payment of Exercise | F | 33.74 | 1,879 | 63,397 | 56,196 | 58.1 K to 56.2 K (-3.24 %) |